A New Fellowship Program at Mount Sinai Will Help Shape the Next Generation of Health Care Leaders

Updated on Oct 25, 2023 | Community, Featured, School

The Graduate Medical Education (GME) program at the Icahn School of Medicine and the Graduate School of Biomedical Sciences have announced the launch of the Health Care Administration, Leadership, and Management Fellowship for early career stage physicians.

This ACGME-accredited fellowship program is designed to offer physicians a comprehensive experience combining the academic rigor of the school’s Masters of Health Administration (MHA) program with hands-on training in Graduate Medical Education. This collaboration will provide fellows with a well-rounded education encompassing leadership development, health care administration, quality improvement, and patient safety, among other critical areas.

“I want to grow as a leader in the next three to five years. I see myself as a physician executive who can help make decisions on how to make health care better and create new health care delivery models that are equitable.” — Shantheri Shenoy, MBBS

“The fellowship is unique because it brings together excellent classroom-based learning and unique rotations across the Mount Sinai Health System, which makes for a physician who is poised to lead,” said Brijen Shah, MD, Fellowship Director, Associate Dean for Graduate Medical Education, and Professor, Medicine (Gastroenterology) at Icahn Mount Sinai. “This program provides a unique chance to get a peek behind the curtain of how health care is delivered and to advance and be part of diverse teams to solve health care problems.”

Shantheri Shenoy, MBBS

The MHA program provides the academic and curricular side of the fellowship requirements, while GME provides experience on the clinical side through rotations in various departments within the Health System.

The fellow will gain practical insights into the operational aspects of managing a health care organization while collaborating with a diverse team of health care professionals. Additionally, the fellow will have access to a network of faculty members, accomplished alumni, and industry experts, who will provide mentorship and guidance. Upon completing the program, the fellow will receive a Masters in Health Administration degree.

The inaugural fellow is Shantheri Shenoy, MBBS, who started the fellowship in September and will be in the program for two years. Dr. Shenoy is the Associate Division Chief of Hospital Medicine at Mount Sinai West and Assistant Professor, Medicine (Hospital Medicine, Nephrology) at Icahn Mount Sinai. She completed her internal medicine internship and residency at Maimonides Medical Center followed by a fellowship in nephrology at New York Medical College – Westchester Medical Center. Dr. Shenoy completed the Greater New York Hospital Association Clinical Quality Fellowship Program in 2019. She has planned and implemented several projects on high-value care and patient safety, and she has presented them at national and international conferences.

“I want to grow as a leader in the next three to five years. I see myself as a physician executive who can help make decisions on how to make health care better and create new health care delivery models that are equitable” she said. “Addressing the social determinants of health and patient safety are focus areas for me.”

Dr. Shenoy said the fellowship offers valuable experience. “I’ve been meeting leaders in my hospital and throughout the Health System,” she said. “My experience was at the hospital level, so this is giving me a good sense of the health care industry overall. The courses are easy to accommodate with my schedule. The fellowship gives me a hands-on experience for what I’m learning in my courses. You get to see what you have learned in theory.”

The fellowship is the result of the Graduate School’s partnering with GME on this first-of-its kind, ACGME-accredited program, according to Brian Nickerson, PhD, JD, who is the MHA Program Director and Senior Associate Dean for Master’s Programs. “It is a truly unique collaboration reflecting Mount Sinai’s commitment to building leadership for tackling today’s complex health care issues,” he said.

“This fellowship will serve as a stepping stone for aspiring physician leaders who seek to make a significant impact in the health care industry,” he added. “By fostering a deeper understanding of health care management principles and fostering strong clinical acumen, fellows will be uniquely positioned to address the challenges and opportunities that lie ahead in health care delivery.”

 

To learn more about the Health Care Administration, Leadership, and Management Fellowship for early career stage physicians, contact Fellowship Director Brijen Shah, MD, Fellowship Director, or Brian Nickerson, PhD, MHA Program Director.

Mount Sinai Researchers Share Thoughts on the Promise of mRNA Technology, a Nobel Prize-Winning Science

Updated on Oct 27, 2023 | Cancer, Featured, Research, Vaccines

Miriam Merad, MD, PhD, the Mount Sinai Professor in Cancer Immunology (left), and Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer Research (right), lead some of the most cutting edge research in mRNA technology at the Icahn School of Medicine at Mount Sinai.

The 2023 Nobel Prize in Medicine was awarded jointly to two researchers, Katalin Karikó, PhD, and Drew Weissman, MD, PhD, for their decades-long work on messenger RNA (mRNA), which ultimately led to the successful development of COVID-19 vaccines that made a huge difference during the pandemic.

The concept of using mRNA to deliver genetic instructions was met with a lot of skepticism in the beginning, says Nina Bhardwaj, MD, PhD, Ward-Coleman Chair in Cancer Research at the Icahn School of Medicine at Mount Sinai. Because these molecules were rapidly degraded by the immune system, they were thought to be too transient to be used to express anything therapeutic, such as antigens or other molecules in immune cells, she added.

“It’s really through the two researchers’ sheer hard work and determination and validation, both in the lab and in the clinic, that this became a technology that can be harnessed for patient benefit,” says Dr. Bhardwaj, who is also Director of Immunotherapy and Medical Director of the Vaccine and Cell Therapy Laboratory.

The validation of mRNA as a delivery mechanism has opened the doors to vaccines in many other diseases, including cancer, says Miriam Merad, MD, PhD, the Mount Sinai Professor in Cancer Immunology, and Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at Icahn Mount Sinai.

“We’ve been quite interested in the mRNA for some time—not only this type but also another called the micro RNA,” says Dr. Merad. Even prior to COVID-19, Mount Sinai researchers have recognized the potential of various RNA for use in vaccines, such as for cancer, she adds.

Read more from Drs. Bhardwaj and Merad on their thoughts on mRNA technology, and learn how Mount Sinai is leading this field with its research.

Katalin Karikó, PhD (left), and Drew Weissman, MD, PhD, were the joint winners of the 2023 Nobel Prize in Medicine. Dr. Karikó, a Hungarian-American biochemist who worked at the University of Pennsylvania, continues her research as a professor at the University of Szeged in Hungary. Dr. Weissman, an immunologist, advances vaccine work at his laboratory at the Perelman School of Medicine at UPenn.

What’s the history of mRNA technology development been like?

Dr. Bhardwaj: There was a lot of skepticism in the beginning about how exogenously-delivered RNA—which we usually think of as these transient molecules that are rapidly degraded—can be utilized to express antigens and other molecules in immune cells. So the concept that could happen was not well accepted initially.

Dr. Merad: Also, much of the early focus was on cancer, and researchers were not obtaining fantastic results. Cancer vaccines are still yielding anecdotal responses, and it might not have anything to do with the technology.

What do you feel was a turning point for that skepticism?

Dr. Bhardwaj: I think, in especially the last decade, this technology was being used a good deal at the National Institutes of Health’s Vaccine Research Center as a platform for developing vaccines against other infectious agents, not COVID-19 at the time. What had been generated from the platform showed promise, in preclinical models.

When the COVID-19 pandemic came along, there were highly immunogenic modified “cassettes” generated wherein one could just plug in antigens—such as the spike protein of the COVID-19 virus—which could be rapidly formulated into vaccines and tested.

But even prior to that, there were ongoing efforts to use this technology as platforms for cancer vaccines, which are now being tested in the clinic with encouraging preliminary results in randomized studies in melanoma.

Dr. Merad: I think the big two were the lipid nanoparticle (LNP) as a delivery mechanism, and of course, a disease that somehow was the perfect case to try this new therapeutic strategy.

Drs. Karikó and Weissman were able to change up the RNA prior to the injections so that the molecules persisted longer. They were making clear advances in the way the proteins were being made. But, still, the real fixes started when they learned to encapsulate the mRNA in nanoparticles.

In fact, Dr. Karikó went to BioNTech (which partnered with Pfizer to produce the COVID-19 vaccine) and Moderna also licensed mRNA technology, and what happened was that two companies developed a way of delivering mRNA. This extra component—the delivery mechanism—was what made therapeutics possible.

Also, the pandemic is kind of a boost for mRNA technology. Because, first, of the number of patients available, and second, we are in a bit of a risk-taking mode. These vaccines were already developed against pathogens, so they just had to be pivoted to COVID-19.

U

One solution that companies like Pfizer/BioNTech and Moderna used to protect the mRNA instructions in their vaccines from being degraded by the immune system was loading them into tiny fat particles known as lipid nanoparticles (LNPs). These delivery vehicles are also able to find the targeted cells, which mRNA molecules alone cannot achieve. Icahn School of Medicine at Mount Sinai honored the efforts of the BioNTech executives during its 54th Commencement in May 2023, conferring upon them honorary Doctor of Science degrees.

Learn more about LNPs and mRNA technology in a Q&A with BioNTech executives

What research is Mount Sinai doing with mRNA?

Dr. Bhardwaj: One exciting line of research includes work from Yizhou Dong, PhD, Professor of Oncological Sciences at Icahn Mount Sinai, who works with the Icahn Genomics Institute and PrIISM. He is one of our newly recruited faculty members, who has been working in this space for quite a while. He has demonstrated that RNA can be used as a platform to introduce various kinds of immune modulators into cells, including dendritic cells, a key cellular potentiator of the immune system.

Dr. Dong uses RNA-LNPs to introduce various types of immune modulators into immune cells and even cancer cells to enhance antitumor immunity. My team is using RNA-LNPs to encode newly identified antigens, such as neoantigens, which arise from mutations in cancer cells, and then use those within vaccine constructs.

In preclinical models, we have shown that such RNA-lipid constructs, developed in-house in The Tisch Cancer Institute, are immunogenic and can have therapeutic benefit in treating cancers. Our goal is to take that to the next level: develop our own vaccine constructs and deliver them into humans.

Dr. Merad: We’ve been interested in exploiting mRNA to translate into specific proteins. We have been very much interested in using mRNA to change the immunosuppressive environment of tumors, where we use mRNA to go into the tumor and start making it look like an infection to induce an antitumor immune response. There is a lot of effort in using mRNA to transform cancer lesions—which can suppress and evade the immune system—into something very inflamed that can be recognized by the immune system and lead to tumor clearance.

One of my colleagues, Brian Brown, PhD, Director of the Icahn Genomics Institute, and Professor of Genetics and Genomic Sciences at Icahn Mount Sinai, is quite interested in using mRNA in different types of disease settings. My lab is mostly looking at inflaming regions in cancer, or reducing inflammation in inflammatory diseases—in this case we use mRNA as cargo to deliver proteins that will dampen inflammation and enable inflammatory lesions to heal.

What do you see as the future of mRNA technology?

Dr. Bhardwaj: I think the breadth is enormous. We can add many different types of immune-enhancing modulators into these particles—not just antigens—including homing receptors and cytokines. RNA platforms have been given intramuscularly and intravenously, and it’s possible you may be able to deliver it intranasally and into the skin, as well as directly into tumors.

The scope of what we can do, what we can encode and add, and the potential combinations with other immunomodulatory agents is vast. I think the field is moving really fast, especially with new companies coming into the field and startups accelerating rapidly.

Dr. Merad: Right now, the big conundrum that we have is: how can we raise an immune response against cancer that is beneficial, without inducing a harmful response against other tissue? I think the answer is delivery.

With mRNA, it provides all the instruction needed for therapeutic effect, but what we are still working on is enhancing that cell-specific delivery system. If we were allowed to bring that instruction to the right compartment, then we can afford to do so much more.

Patient Recovers From Two Brain Surgeries With Help From “Wonderful” Mount Sinai Team

Updated on Oct 24, 2023 | Featured, Stories of Excellence

Shannon Hickey, patient, right, with her occupational therapist, Aura Weltman

Shannon Hickey, 29, never imagined a case of double vision shortly before Valentine’s Day in February would lead to an Emergency Department visit, two brain surgeries, and months of rehabilitation therapy. It has been a long journey, made easier by her medical team, and on one memorable day, by an unexpected word of kindness and cheer.

Shannon had always been very healthy, and only a week before her symptoms began, she was sightseeing in Paris with her best friend. At most, Shannon thought her symptoms might simply be due to a vitamin deficiency. Imaging revealed that was not the case. She had a brainstem brain tumor, and on February 14, Shannon underwent surgery to remove the tumor at The Mount Sinai Hospital, performed by a team headed by Isabelle Germano, MD, MBA, Director of the Mount Sinai Comprehensive Brain Tumor Center. When she awoke, her double-blind vision was much improved but she developed a new difficulty with her peripheral vision on the right. She also had difficulty recalling words and moving the right side of her body, as consequence of a small stroke that occurred during surgery. After a few days in the Intensive Care Unit, Shannon spent two weeks as an inpatient in the Rehabilitation Unit at the hospital.

Shannon describes herself as extraordinarily positive, and says she never felt the severity of all she was going through. “A right-sided deficit was fortunate,” she says. “I am left -handed.” And she gives a lot of credit to her “wonderful” team of therapists. Shannon praises Emily Teitelbaum, MS, OTD, Senior Occupational Therapy Rehabilitation Specialist, “Emily was my inpatient OT. She had been a professional ballet dancer before becoming an OT, and I was a volunteer dance instructor, so Emily designed my exercises based on ballet moves, which clearly were personalized for me. It was just so nice.”

“My physical therapist, Will Long PT, DPT, was such a happy and positive person,” Shannon continues. “He made everything fun. I had to learn all the basics, basically how to walk again, but it never felt like work.”

“It was an amazing meeting, to have all of these professionals, in one room, in person and virtually, supporting me in this way.”

Shannon returned home in late March, but needed to continue physical and speech rehabilitation therapy. She still required a brace to walk and had challenges reading. As the spring progressed, Shannon was eager to return to work despite her limitations, as she had taken a three-month leave and wanted to meet her self-imposed deadline. At that point, my wonderful outpatient occupational therapist, Aura Weltman, MS, Senior Occupational Therapy Rehabilitation Specialist was instrumental in my emotional recovery as well as my progress physically. Shannon says. “She set up an interdisciplinary meeting with my team, including my therapists, social worker, and Aveniel Klein, MD, PhD, Associate Professor, Rehabilitation and Human Performance. They helped me understand that I was doing all the work I needed to do to recover, but there was no timeline I could measure myself against. I needed to be patient. It was an amazing meeting, to have all of these professionals, in one room, in person and virtually, supporting me in this way.”

Unfortunately, the tumor had formed another cyst in her thalamus, so a second surgery was scheduled for June. Shannon admits she was nervous this time. “I had so many changes after the first surgery, I was scared.” But she says, she felt incredibly supported by the Mount Sinai team she had come to consider family. She recounts a small, but meaningful gesture by Dr. Germano. “I gave Dr. Germano a valentine on the day of my first surgery. For the second surgery, she was wearing a Snoopy surgical cap and told me she knew I liked Snoopy. I was confused, but a few minutes later, I recalled I had given her a Peanuts valentine featuring Snoopy. It was incredibly sweet of her.”

During this surgery, a biopsy confirmed that Shannon had pilocytic astrocytoma, a type of brain tumor that originates from glial (brain) cells called astrocytes and seen primarily in children. Most cases are benign, as was Shannon’s. Shannon says the day she was informed of her diagnosis was “the best day of my life.” She explains, “It was my lucky day to learn this tumor does not multiply. Literally, I can thank my stars, because these glial cells are star-shaped.”

Shannon is taking oral targeted-therapy specific for her tumor’s molecular signature and may have long-term decreased peripheral vision on the right side. But she remains upbeat and unfazed. “I have adapted to my vision deficit. I no longer need speech therapy and will cut back on OT soon,” she says. “And, I am so lucky, the hospital is near my home so I get to practice walking on my way to PT.”

Shannon with Prince Allah, parking attendant

Shannon is grateful to another special Mount Sinai staff member: On her walks back home along Fifth Avenue after therapy, she says she had to be hyper-focused to avoid falling. “I could not really pay attention to my surroundings or people.” But one day, she heard someone say to her: “Oh, progress.” The voice was that of Prince Allah, a parking attendant at 1176 Fifth Avenue. Shannon introduced herself, and thanked Prince for his interest and support. Prince says he had seen Shannon walk by for months, first on crutches, and then on her own, and noted how she worked at her gait, but still had her smile.

“I could not hold back, I had to tell her she was so impressive,” he says. “And when she came up and introduced herself, it made my day.” Mount Sinai is his first hospital work experience. “I love working at The Mount Sinai Hospital,” he says, “helping people in any way I can.”

Read more Stories of Excellence.

Diversity Innovation Hub Holds 2023 Pitch Day Competition Recognizing Innovation and Entrepreneurship

Updated on Oct 19, 2023 | Community, Diversity and Inclusion, Featured

From left: Gary C. Butts, MD, Thandiwe-Kesi Robins and Ashley Abid of Skinterest; Michelle Ng of Neuemoon Health; Jiye Son, PhD of Keratin Nails; and Fariha Ahsan and Carmen Minsal from Mount Sinai’s Diversity Innovation Hub.

Mount Sinai’s Diversity Innovation Hub (DIH), a venture of the Office for Diversity and Inclusion, is a unique, community-driven incubator with the goal of increasing the diversity of founders in health care innovation and entrepreneurship through investing and growing ideas that disrupt inequities caused by social determinants of health.

On Thursday, September 21, DIH members, including Gary C. Butts, MD, Executive Vice President for Diversity, Equity, and Inclusion and Chief Diversity and Inclusion Officer at the Mount Sinai Health System, Fariha Ahsan, MS, DIH Director, and Carmen Minsal, MHA, DIH Program Manager, showcased 12 first-time entrepreneurs for the 2023 Pitch Day Competition.

About 100 people representing industry leaders from Mount Sinai, health start-ups, and venture capital firms gathered at the offices of Company Ventures in New York to watch teams pitch in three  categories: Gender Equity, Innovation and Community Impact. The event included $10,000 prizes for winning teams.

The event featured keynote speaker Magdala Chery, DO, MBS, MPH, Health Equity Clinical Specialist at Google. “A lot of time as founders and innovators you’re solving a thing that is so close and dear to you, but you don’t talk about how it affects you,” she said in her remarks. “Know your story, understand your story, and tell your story.”

Here are the winners:

  • Founder Jiye Son, PhD, founder of Keratin Nails, won the Community Impact award. Keratin Nails aims to reduce health disparities for nail salon workers by creating non-toxic nail polish and raising awareness on the harmful exposure to nail products through tech-enabled education.
  • Ashley Abid and Thandiwe-Kesi Robins, co-founders of Skinterest, won the Innovation award. The company is a joint venture, founded by two women of color, breaking barriers for dermatology care of patients of color.
  • Michelle Ng, founder of Neuemoon Health, won the Gender Equity award. Neuemoon Health addresses the patient care gap for women with endometriosis and uterine fibroids.

View photos from the event

PreviousNext
12345678
Learn more about Mount Sinai's Diversity Innovation Hub

Lab Coat Ceremony for PhD and MD/PhD Students Marks the Start of New Journeys in Research and Training

Updated on Oct 13, 2023 | Featured, Research, School

Amid cheers and applause, first-year PhD students and third-year MD/PhD students received crisp white lab coats to mark the start of their journeys into academic research and training during a recent ceremony held by the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai. The lab coats symbolize the professionalism and authority that trainees will develop and nurture during their time at Mount Sinai.

“Our PhD programs in biomedical sciences, neuroscience, and clinical research provide rigorous collaborative training that prepares our students to spearhead the next generation of scientific and medical breakthroughs,” said Marta Filizola, PhD, Dean of the Graduate School of Biomedical Sciences and the Sharon & Frederick A. Klingenstein-Nathan G. Kase, MD Professor as she welcomed the students, faculty, and guests.

Marta Filizola, PhD

Today’s biomedical and clinical research efforts, she said, must help “solve complex problems and find solutions grounded in data and their rigorous statistical analysis. We are branching out into new realms of research that leverage artificial intelligence and other emerging technologies in medicine to improve patient health and quality of life. Our students are a crucial part of this growth.” Dr. Filizola is also Professor of Pharmacological Sciences, Neuroscience, and Artificial Intelligence and Human Health.

Eric J. Nestler, MD, PhD, Dean for Academic Affairs at Icahn Mount Sinai, and Chief Scientific Officer for the Mount Sinai Health System told the students: “We want you to aim high…Don’t settle on a project because it’s easy and doable. Instead, take a chance by studying something that in its own small way will change the world.”

Why a PhD in Biomedical Sciences? Click here to read how student Mount Sinai lnspired student Ashley Richardson to study immunology and microbiology.

Dr. Nestler said, “I’ve given a lot of thought over the years to what constitutes the essential ingredients for such an undertaking. First, is novelty. Dr. Albert Einstein once said, ‘If you do what you always did, you will get what you always got.’” He also mentioned relevance of the work, technical innovation, creativity, collaboration, perseverance—and “having an available and generous principal investigator and other members of your lab who can also help with brainstorming, troubleshooting, and collaborative experiments [and who] should also support your goals of thinking big, having big expectations for yourself, and publishing your work as high-impact papers in respected, peer-reviewed journals.” Dr. Nestler is also Director of The Friedman Brain Institute and Nash Family Professor of Neuroscience at Icahn Mount Sinai.

Eric J. Nestler, MD, PhD

Genomic scientist Brynn Levy, M.Sc.(Med), PhD, FACMG, who received his PhD degree in clinical cytogenetics from Mount Sinai in 1999 and is world-renowned in the clinical utility of genomic technologies in reproductive medicine, gave an insightful speech about his own educational journey and experiences.

“The first piece of advice I have for you is: be an active participant in your profession, and get involved. As you begin to entrench yourself in your profession, try to be more than just a sideline observer,” he told the students. Also, “It’s important to enjoy what you do” and to “treat every day as a learning experience. Identify great mentors and embrace them, as great mentors teach you more than just medicine and science.”

Dr. Levy is Professor of Pathology and Cell Biology at the Columbia University Irving Medical Center (CUIMC), Medical Director of the Clinical Cytogenetics Laboratory at New York Presbyterian Hospital, and Co-Director of the Laboratory of Personalized Genomic Medicine at CUIMC.

Dr. Levy said that he was fortunate to have “two amazing mentors”—the late Kurt Hirshhorn, MD, at Mount Sinai, and the late Dorothy Warburton, PhD, at Columbia, each a trailblazing researcher in the cytogenetics field.

Dr. Hirshhorn was a legendary pediatrician, medical geneticist, and cytogeneticist known for groundbreaking research during his 50-year career at Mount Sinai, which included establishing one of the first laboratories in the nation for clinical chromosome studies. Among his many honors, he was a member of the National Academy of Medicine. “Kurt led by example,” said Dr. Levy. “Over and above his phenomenal accomplishments and knowledge, he taught me how to have confidence in myself. He never micromanaged me, and instead, he gave me autonomy…He taught me the meaning of paying it forward, possessing the insight of the importance of investing in the next generation.”

Brynn Levy, M.Sc.(Med), PhD, FACMG

Dr. Levy concluded: “As you all embark on the exciting new pathway that you’ve chosen for yourselves, I hope you invest in yourselves. Get involved in your field and engage with your community and colleagues. Be curious and treat every day as a lesson in medicine, science, as well as life. Know your limitations, and see those around you as a resource to continuously improve who you are and what you do. In doing so, I trust that every day will be fulfilling, and you will no doubt make an indelible impact on many patients’ lives and on society as a whole.”

With great fanfare, each student was presented with a lab coat, an effort sponsored annually by the Mount Sinai Alumni Association. Standing together and wearing their lab coats, they recited the PhD Oath in unison. “With my Doctor of Philosophy, I willingly pledge to uphold the highest levels of integrity, professionalism, scholarship, and honor,” they said, as they read a set of guiding principles that would start them on their journeys to rewarding and enjoyable careers.

A slideshow of snapshots from the Lab Coat Ceremony

PreviousNext
12345

How Mount Sinai is Using Artificial Intelligence to Improve the Diagnosis of Breast Cancer

Oct 11, 2023 | Featured, Your Health

Laurie Margolies, MD, a radiologist who is Chief of Breast Imaging at the Dubin Breast Center and Vice Chair, Breast Imaging, Mount Sinai Health System

More and more people are getting mammograms as the population ages, as more younger people are choosing to get screened, and as the benefits of accurate screening and early detection of breast cancer remain clear.

Breast cancer is the most common cancer among women in the United States, except for skin cancer. Each year, about 240,000 cases of breast cancer are diagnosed in women (and about 2,100 in men), according to the U.S. Centers for Disease Control and Prevention.

In response to this growing need, Mount Sinai has expanded its network of breast imaging sites, and  has deployed a new tool: artificial intelligence.

In this Q&A, Laurie Margolies, MD, a radiologist who is Chief of Breast Imaging at the Dubin Breast Center and Vice Chair, Breast Imaging, Mount Sinai Health System, explains how radiologists at the Mount Sinai Breast Cancer of Excellence for Breast Cancer are leveraging the power of artificial intelligence to achieve a more precise diagnosis, which allows surgeons and oncologists to start the right treatment sooner, giving patients the best possible outcome.

How does AI help patients in the diagnosis of breast cancer?

AI is a new tool that gives a second opinion on a mammogram. It assists the radiologist, it does not replace the radiologist. It’s like having a very well trained senior fellow sitting next to you. Multiple studies have shown that when you have radiologists working with AI, you find more breast cancers, and often smaller cancers. What’s great about AI is that it never gets tired, it can’t get distracted. But there’s no substitute for the experience of the radiologist.

How does it help with “call backs”?

This additional review can help radiologists determine instances where there is a very low probability of cancer. This helps to reduce the number of times that patients will be asked to return for another procedure to get a closer look at an area of possible concern, which many know as a “call back.” Fewer than 10 percent of women who are asked to return are typically found to have cancer. But these extra screenings make people anxious, they cost money, and they fill our breast centers with people who don’t need to be there.

How does AI work? What does the patient see?

Patients will not see any difference in the process. As your radiologist is reading your mammogram or sonogram on their computer, they can access a special program that will also review the scan. It takes a few extra minutes. In many cases, AI reviews the scan before the radiologist and highlights areas for the radiologist to pay extra attention.

Who can access this service?

Anyone who receives a mammogram or breast ultrasound performed at Mount Sinai will have access to this AI capability. There is no extra cost to patients.

Learn more about Mount Sinai's Center of Excellence for Breast Cancer

Pin It on Pinterest